Award winning design for easy application

Transcription

1 Award winning design for easy application 1 Bottle = 1 treatment course 1 Press = 1ml treatment dose Flexible atraumatic nozzle for accurate delivery. Grip to avoid finger slipping. 1ml airless pump for precise dosage measurement with every press. (The pump must be primed with two presses before administration of first dose.) Effective application in all orientations. Airless bottle: Hygienic, prevents retro contamination, i.e. no draw back. Enables accurate 1ml dose dispensing whatever its orientation. Triple action combination of ingredients for rapid effective treatment. Bottle shape facilitates easy handling and use. easotic delivers 1ml per press every time. Is 1ml appropriate for all dogs? Yes! 1ml achieves sufficient coverage of the target area (ear canal lining) whatever the dog breed. 1,3 It takes 0.5ml 1ml of medication to get down to the tympanic membrane in medium / large sized dogs. 1 Not all products are the same! Dosing with conventional products is very imprecise and easotic uniquely delivers an appropriate dose every time. Dr T Nuttall BSc BVSc PhD CertVD CBiol MIBiol MRCVS, University of Liverpool Product Vol / drop or press (SPC) Label dose Total volume administered Administration frequency/ day Duration of administration easotic 1 ml 1 ml 1 ml 1 5 days Product A ml 10 drops 0.24 ml 1 7 days Product B ml 4-8 drops ml 2 7 days Product C? 5-10 drops? days Product D ml 10 drops ml days It takes around 40 drops of other products to make a 1ml volume.

2 Features Advantages Vet Benefits Owner easotic Innovative Award Winning Packaging 1ml pump delivery system Consistent dosing. Flexible atraumatic nozzle Airless pouch Ergonomic bottle Reduce potential for pain during administration. Apply the product whatever the position of the dog. No retro-contamination. Easy to handle and use. Better product administration. Correct dosage administered. Sufficient volume to coat ear canal. Offers an easy to use ear product to maximise compliance for all customers. Ease of use, no worry about administering the correct dose. Less anxiety for the pet owner and less stress for the pet. easotic Treatment Regime One press (1ml)/ ear /day for 5 days Shortest, licensed, effective treatment duration available. Better compliance with treatment. Reduces inconvenience for clients and reduces the risk of forgetting to treat. easotic Formulation - Triple Action Ingredients HCA High potency topical steroid Gentamicin First choice antimicrobial ear therapy 17 Miconazole Proven antifungal agent 14 Specific metabolism in the skin 15, very high safety profile. Safer than Betamethasone. 16 Wide spectrum of activity against gram negative bacilli and gram positive cocci. 4 Highly effective against Malassezia pachydermatis. Meeting client expectations by prescribing a product that gives rapid relief from pain and irritation, combined with control and resolution of complicated infections. Stops animal pain rapidly. The pet is more comfortable in a short period of time. References 1. Bloom P. Practical approach to diagnosing and managing ear disease in the dog. Michigan Veterinary Conference, Barasch A, Griffin AV. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. Future Microbiol., 2008; 3: Dickson DB, Love DN. Bacteriology of the horizontal ear canal of dogs. Journal of Small Animal Practice, 1983; 24: Forsythe WB. Tympanographic volume measurements of the canine ear. American Journal of Veterinary Research., 1985; 46(6): Foster AP, DeBoer DJ. The role of Pseudomonas in canine ear disease. Compendium of Continuing Education for the Practicing Veterinarian, 1998; 20: Hariharan H, McPhee L, Heaney S, Bryenton J. Antimicrobial drug susceptibility of clinical isolates of Pseudomonas aeruginosa. Canadian Veterinary Journal, 1995; 36: Kiss G, Radvanyi S, Szigeti G. New combination for the therapy of canine otitisexterna. I- Microbiology of otitis externa. Journal of Small Animal Practice, 1997; 38: Kwocka, K. W. Managing Otitis Externa and Media I & II. George H Muller Veterinary Dermatology Seminar, Hawaii, Oct 31 Nov 9. Radlinsky MA and Mason DE. Diseases of the ear. In: Ettinger SJ and Felman EC. Textbook of Veterinary Internal Medicine 6th edition, Saint Louis, 2005, Rougier S and al. A comparative study of two antimicrobial/anti-inflammatory formulations in the treatment of canine otitis externa. Veterinary Dermatology, 2005; 16: Schick AE, Angus JC, Coyner KS. Variability of laboratory identification and antibiotic susceptibility reporting of Pseudomonas spp. isolates from dogs with chronic otitis externa. Veterinary Dermatology, 2007; 18: Seol B, Naglic T, Madic J, Bedekovic M. In vitro antimicrobial susceptibility of 183 Pseudomonas aeruginosa strains isolated from dogs to selected antipseudomonal agents. J Vet Med, 2002; B49: Strain GM, Merchant SR, Neer M, Tedford BL. Ototoxicity assessment of gentamicin sulfate otic preparation in dogs. American Journal of Veterinary Research, 1995; 56: Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use in animal health - chemical, biochemical and pharmalogical aspects. J. Vet Pharmacol Therap., 2003; 26: Schackert C, Korting HC, Schäfer-Korting M. Qualitative and quantitative assessment of the benefit/risk ratio of medium potency topical corticosteroids in vitro and in vivo. BioDrugs, 2000; 13: Luger T, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, Krutmann J, Niedner R, Röcken M, Ruzicka T, Schwarz T. Topical skin therapy with glucocorticoids--therapeutic index. J Dtsch Dermatol Ges, 2004; 2(7): Bass M. Step-by-step management of otitis externa in dogs. Veterinary Medicine, 2004; 99(3): Swinney, A., Fazakerley, J., McEwan, N. and Nuttall, T (2008) Comparative in vitro antimicrobial efficacy of commercial ear cleaners. Veterinary Dermatology, Vol 19(suppl 1): Nuttall, T. J., Mueller, R., Bensignor, E., Verde, M., Noli, C., Schmidt, V., Reme, C. (2009) Efficacy of a % hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo controlled trial. Veterinary Dermatology (In Press). POM-V Easotic contains Hydrocortisone aceponate 1.11mg, Miconazole nitrate 15.1mg, Gentamicin sulphate 1505IU. For information on EASOTIC please contact: Virbac Ltd. Woolpit Business Park, Windmill Avenue, Woolpit, Bury St. Edmunds, Suffolk IP30 9UP Tel:

3 NEW Don t guess! One Press, No Mess, Less Stress. One Press Once-a-day for five days. Designed for convenience, because life s too short to count drops.

4 Better compliance, assured dosage. Predisposing: Ear canal conformation Swimming Environmental conditions Primary: Hypersensitivity disease (atopy, food, contact) Parasites / Foreign bodies Systemic disease Perpetuating: Infection - Bacteria (Gram +ve & -ve) 3, 5, 8, 9 - Yeasts Inflammation Otitis media Incorrect initial treatment and lack of on going maintenance Proliferative changes INFECTION INFLAMMATION Original treatment incorrect Lack of post treatment maintenance Underlying disease undiscovered Proliferative changes RELAPSE CYCLE OF REINFECTION MANAGEMENT & TREATMENT Cleaning of the ear Treatment of underlying conditions Surgery may be required Break the cycle and simplify thetreatment. easotic provides fast and effective relief. DIFFICULTIES & NON- COMPLIANCE Pain Orientation Dose measurement Administration Duration of Treatment Client compliance Don t Guess = consistent dosing every time with each administration One Press = 1 ml dose No Mess = effective application at any angle, precise ergonomic nozzle Less Stress = reduced frequency and duration of treatment, easier for owners and pets 1 Bottle = 1 treatment course Active Ingredients HCA Gentamicin Miconazole Increased compliance compared to twice daily drops treatment* * European field trial. Treating otitis externa has never been so easy!

5 Formulated for fast effective treatment. Highly effective against inflammation, bacteria and yeast Unique, potent anti-inflammatory agent HCA. Potency comparable to that of dexamethasone. Excellent safety profile. 19 Specific metabolism in the skin. 15 Principle component of Cortavance. Gentamicin sulphate as an agent of choice for mixed infections. Safety documented in numerous studies. No vestibulotoxic or ototoxic effects. 13 Well-established 9 and considered as a first-choice antimicrobial. 17 Continuing low resistance and effectiveness against Pseudomonas. 6, 7, 11, 12 Activity against a wide range of gram-positive and gram-negative aerobic bacteria. Miconazole nitrate. Broad spectrum antifungal and bactericide against gram positive organisms. Low-level resistance 2 and convincing safety profile. 14 The special composition ensures excellent adherence in the ear canal. Clinical Efficacy Trial A 5-day course with easotic is comparable to a 7-day course with other brands Days of treatment Reduction of clinical score (%) final day of easotic treatment final day of Product A treatment easotic / 5 days group. n=34 HCA, Gentamicin, Miconazole. Dose regime: 1ml / day for 5 days Triangle indicates an examination Product A. n=34 Dexamethasone, Marbofloxacin, Clotrimazole. Dose regime: 10 drops / day for 7 days Circle indicates an examination 1ml of easotic per day for 5 days had lower clinical score measurements for pruritus, pain, excoriation, erythema, exudate, stenosis and suppuration, than Product A (10 drops per day for 7 days) and was comparable at follow up on day 14.

6 Controls Malassezia within 15 minutes. Concentration (CFU/ml) Malassezia 5 min. 15 min. 30 min. easotic Ingredients: HCA, Gentamicin, Miconazole Product B Ingredients: Betamethasone, Gentamicin, Clotrimazole Product A Ingredients: Dexamethasone, Marbofloxacin, Clotrimazole Complete antifungal activity was recorded within 15 minutes of incubation only with easotic. European field trial Offers x 10 better compliance with superior antimicrobial efficacy Inclusion criteria HCA, Gentamicin, Miconazole Product B: Betamethasone valerate, Gentamicin, Clotrimazole Bacterial and/or fungal otitis externa Treatment groups Dose regime (SPC) 88 dogs 1ml / ear / day for 5 days, for all size dogs 88 dogs <15kg 4 drops / ear twice a day for 7 days >15kg 8 drops / ear twice a day for 7 days Protocol Scoring Results 5 clinical examinations were performed over a 49 day period. On days 0, 14 & 49 samples were submitted for culture and sensitivity tests. Eight clinical parameters were scored according to severity. No significant difference between treatments in all clinical parameters measured A significantly* higher number of dogs showed microbial score improvement with easotic than Product B Number excluded due to non compliance n = 1 (~1% of dogs) n = 10 (~11% of dogs) x10 BETTER COMPLIANCE WITH *(P=0.0295)